Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown … Continua a leggere

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

No approved targeted therapy for the treatment of patients with neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS)-mutant melanoma is currently available. In this phase Ib escalation/expansion study (ClinicalTrials.gov identifier: NCT02974725), the safety, tolerability, and preliminary antitumor activity of naporafenib (LXH254), a BRAF/CRAF protein kinases inhibitor … Continua a leggere

Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review

Immune checkpoint inhibitors (ICI) and targeted therapies (TT) have significantly improved disease control and survival in people with stage III and IV cutaneous melanoma. Understanding the impact of therapy on health-related quality of life (HRQL) is vital for treatment decision-making and determining targets for supportive care intervention. We conducted a mixed-methods systematic review to synthesise the impact of ICIs and TT … Continua a leggere

FoxP3 Expression in Tumor-Infiltrating Lymphocytes as Potential Predictor of Response to Immune Checkpoint Inhibitors in Patients with Advanced Melanoma and Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICI) are the main therapy currently used in advanced malignant melanoma (MM) and non-small cell lung cancer (NSCLC). Despite the wide variety of uses, the possibility of predicting ICI efficacy in these tumor types is scarce. The aim of our study was to find new predictive biomarkers for ICI treatment. We analyzed, by immunohistochemistry, various cell subsets, including CD3+, CD8+, CD68+ …  Continua a leggere

Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma

Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-free survival rates for surgery alone range from 40 to 59% and 30 to-39%, respectively. The current standard of care is therapeutic lymph node dissection (TLND) followed by a year of adjuvant systemic therapy. Multiple phase 2 trials have shown that neo-adjuvant immunotherapy induces major pathologic response (MPR) rates (pathologic complete … Continua a leggere

Come ottimizzare la conduzione e la gestione di un trial clinico oncologico
I mercoledì dell’oncologia
Webinar (non ECM), 26 aprile 2023 dalle 17.00 alle 18.15

Liver transplantation in patients with hepatic metastases from colorectal cancer
I mercoledì dell’oncologia
Webinar (non ECM), 3 maggio 2023 dalle 17.00 alle 18.15

2023 Cancer Research: from Orlando to Palermo
News from AACR Annual Meeting 
Palermo, 5 – 6 maggio 2023

Il trattamento dei tumori del timo: parole chiave rete e multidisciplinarietà
I mercoledì dell’oncologia
Webinar (non ECM), 10 maggio 2023 dalle 17.00 alle 18.15

Il Melanoma ed i Tumori della Cute: percorsi diagnostici e novità terapeutiche
Bari, 12 – 13 maggio 2023

L’oncologia tra i successi di oggi e i traguardi di domani
La Spezia, 18 – 20 maggio 2023

11th Meeting on External Quality Assessment in Molecular Pathology
Napoli, 19 – 20 maggio 2023